Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma.
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
12 09 2019
12 09 2019
Historique:
received:
21
05
2019
accepted:
10
07
2019
pubmed:
20
7
2019
medline:
24
1
2020
entrez:
20
7
2019
Statut:
ppublish
Résumé
Chimeric antigen receptor (CAR) T cells targeting CD19 have emerged as a leading engineered T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. The phase 1/2 clinical trials that led to US Food and Drug Administration approval excluded patients with central nervous system (CNS) involvement, due to strict eligibility criteria. Here, we report on our institutional experience with 8 secondary CNS lymphoma patients treated with commercial tisagenlecleucel. No patient experienced greater than grade 1 neurotoxicity, and no patient required tocilizumab or steroids for CAR T-cell-mediated toxicities. Biomarker analysis suggested CAR T-cell expansion, despite the absence of systemic disease, and early response assessments demonstrated activity of IV infused CAR T cells within the CNS space.
Identifiants
pubmed: 31320380
pii: S0006-4971(20)30006-9
doi: 10.1182/blood.2019001694
pmc: PMC7022436
doi:
Substances chimiques
Receptors, Antigen, T-Cell
0
tisagenlecleucel
Q6C9WHR03O
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
860-866Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 by The American Society of Hematology.
Références
Blood. 2019 May 16;133(20):2212-2221
pubmed: 30808634
Blood. 2016 Sep 15;128(11):1533
pubmed: 31265503
Nat Med. 2018 Jun;24(6):731-738
pubmed: 29808005
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638
pubmed: 30592986
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Nat Med. 2018 Jun;24(6):739-748
pubmed: 29808007
N Engl J Med. 2017 Aug 24;377(8):783-784
pubmed: 28834486
Blood. 2017 Nov 23;130(21):2317-2325
pubmed: 28935694
Cancer Discov. 2016 Jun;6(6):664-79
pubmed: 27076371
Cancer Discov. 2017 Dec;7(12):1404-1419
pubmed: 29025771
Cancer Discov. 2018 Jan;8(1):4-5
pubmed: 29208604